Drug Profile
Umbilical cord mesenchymal stem cell therapy - Sclnow Biotechnology
Alternative Names: 19#iSCLife®-CSD; Cord blood stem cell therapy - Sclnow Biotechnology; hUC Mesenchymal Stem Cells - Sclnow Biotechnology; hUC-MSC; hUC-MSC - Sclnow Biotechnology; Human umbilical cord mesenchymal stem cells - Sclnow Biotechnology; SCLnow 19; Umbilical cord derived allogeneic mesenchymal stem cells therapy - Sclnow BiotechnologyLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Sclnow Biotechnology
- Class Antineoplastics; Heart failure therapies; Hepatoprotectants; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Wounds
- Phase II Osteoarthritis; Primary ovarian insufficiency
- No development reported Cerebral infarction; Femur head necrosis; Heart failure; Liver cirrhosis; Myelodysplastic syndromes
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Cerebral-infarction in China (IV, Injection)
- 28 Nov 2021 No recent reports of development identified for phase-I development in Liver-Cirrhosis in China (IV, Injection)
- 21 Sep 2021 Sclnow Biotechnology completes a phase III trial in Wounds in China (Intrauterine) (NCT03386708)